Researchers have uncovered a new pathway via which cancer cells evade the effects of radiation by deploying self-inflicted – but reversible – DNA breaks to stop the cell cycle and ensure their survival.
Screening a panel of potential autoantigens, investigators at the Karolinska Institute have identified four autoantigens that are targeted by the T cells of multiple sclerosis patients.
Antibiotics drugs discovery, Ursula Theuretzbacher told the audience at the 2022 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), has more than one challenge to overcome.
Researchers from the Center for Genome Engineering within South Korea's Institute for Basic Science have developed a new gene-editing platform that could be the final missing piece of the puzzle in gene-editing technology, by making editing of mitochondrial DNA possible.
A new animal model of systemic lupus erythematosus (lupus) could be useful for understanding the disparity of the disorder, which is vastly more common in women than men.
A research team led by neuroscientists and neurosurgeons from Paris-Saclay University have recently managed to demonstrate that electrical stimulation of the thalamus can restore consciousness when this has been impaired.
Researchers led by Doron Merkler from the University of Geneva have shown how post local infection, a fraction of resting CD8+ tissue resident memory cells cross-reacted with antigens of the CNS to become subsequently activated and drive immunopathological responses in the CNS.
By altering the balance between neuronal excitation and inhibition, researchers have reduced cell death and improved outcomes in animal models of stroke.
Solid tumors have been a tougher nut to crack for CAR T cells than B-cell cancers, for two main reasons. Solid tumors have an inhibitors microenvironment that has made it difficult to get durable responses. And identifying antigens as specific as the B-cell markers CD19 and CD22 has been challenging, leading to problems with on-target, off-tumor toxicity.
Perkinelmer Inc. said the Vega is a first-of-its-kind preclinical ultrasound system that will accelerate preclinical research and drug development studies of cancer, cardiovascular, liver, kidney and other diseases. The imaging platform combines hands-free automation with high-throughput capability, which the company said is a major advance over manual ultrasound scanning across the bodies of individual lab mice.
RSS
